Skip to main navigation Skip to search Skip to main content

The European Lead Factory: Results from a decade of collaborative, public–private, drug discovery programs

  • European Lead Factory Consortium
  • , Herman van Vlijmen*
  • , Andrew D. Pannifer
  • , Phil Cochrane
  • , Daniel Basting
  • , Volkhart M. Li
  • , Ola Engkvist
  • , Jean Yves Ortholand
  • , Markus Wagener
  • , James Duffy
  • , Dirk Finsinger
  • , Jeremy Davis
  • , Steven P. van Helden
  • , Jon S.B. de Vlieger
  • *Corresponding author for this work
  • Johnson & Johnson
  • BioCity Scotland
  • Bayer AG
  • AstraZeneca
  • EDELRIS
  • Grunenthal GmbH
  • Medicines for Malaria Venture
  • Merck KGaA
  • UCB S.A.
  • Pivot Park Screening Centre
  • Lygature

Research output: Contribution to journalReviewpeer-review

49 Downloads (Orbit)

Abstract

The European Lead Factory (ELF) is a consortium of universities and small and medium-sized enterprises (SMEs) dedicated to drug discovery, and the pharmaceutical industry. This unprecedented consortium provides high-throughput screening, triage, and hit validation, including to non-consortium members. The ELF library was created through a novel compound-sharing model between nine pharmaceutical companies and expanded through library synthesis by chemistry-specialized SMEs. The library has been screened against ∼270 different targets and 15 phenotypic assays, and hits have been developed to form the basis of patents and spin-off companies. Here, we review the outcome of screening campaigns of the ELF, including the performance and physicochemical properties of the library, identification of possible frequent hitter compounds, and the effectiveness of the compound-sharing model.

Original languageEnglish
Article number103886
JournalDrug Discovery Today
Volume29
Issue number3
Pages (from-to)16
ISSN1359-6446
DOIs
Publication statusPublished - 2024

Keywords

  • Compuond sharing
  • Drug discovery
  • High-throughput screening
  • Public-private partnership

Fingerprint

Dive into the research topics of 'The European Lead Factory: Results from a decade of collaborative, public–private, drug discovery programs'. Together they form a unique fingerprint.

Cite this